tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Vertex Pharmaceuticals announces EC approval for Alyftrek for CF treatment

Vertex Pharmaceuticals (VRTX) announced that the European Commission has granted approval for Alyftrek for the treatment of people with cystic fibrosis ages six years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator gene.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1